Celldex Therapeutics (CLDX) Equity Ratio (2016 - 2025)
Celldex Therapeutics (CLDX) has 16 years of Equity Ratio data on record, last reported at 0.9 in Q4 2025.
- For Q4 2025, Equity Ratio fell 4.09% year-over-year to 0.9; the TTM value through Dec 2025 reached 0.9, down 4.09%, while the annual FY2025 figure was 0.9, 4.09% down from the prior year.
- Equity Ratio reached 0.9 in Q4 2025 per CLDX's latest filing, down from 0.92 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.97 in Q1 2024 and bottomed at 0.88 in Q3 2023.
- Average Equity Ratio over 5 years is 0.93, with a median of 0.93 recorded in 2022.
- Peak YoY movement for Equity Ratio: increased 19.13% in 2021, then decreased 5.9% in 2023.
- A 5-year view of Equity Ratio shows it stood at 0.94 in 2021, then fell by 1.97% to 0.92 in 2022, then decreased by 0.33% to 0.92 in 2023, then increased by 2.29% to 0.94 in 2024, then fell by 4.09% to 0.9 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.9 in Q4 2025, 0.92 in Q3 2025, and 0.95 in Q2 2025.